now, bristol meyers is interesting, one of the leaders in oncology, bristol myers and lung therapy, the stock fell today. and early stage trial from a company called insight, that stock also down today. but that was a very, very small study. only in eight patients and we should see updated data at the meeting. new positive study from astrazeneca, of course this is very important in the context of pfizer's $106 billion bid for the company. astrazeneca putting a lot of kba citizen on its pipeline saying it could bring billions in sales. in an interesting twist we saw the rise of a small company called clovis, which has a similar drug. so that stuck went way up. >> all right, thank you very much. to read more about the companies working on cancer treatments head to our website at nbr.com. >>> and coming up. the fight for your car's dashboard and why apple wants it to look like an iphone. >>> general motors has already recalled 8 million cars this year alone and just today, five more recalls were announced. adding another 2.7 million vehicles to the list. today's new recalls involve cadilla

and the big mover, that was bristol meyers got downgraded after the data, with the immuno therapy.do that after the downgrade. >> thanks for that. one thing you notice about the charts, most of the names peaked beginning of march. so will this help? >> yeah, the big space in biotech was specifically the oncology drugs. the cancer drugs in particular. that was the growth opportunities. they trade at astonishing multiples because their speculative. based on the forecast that these things are going to come up. a lot of companies in the same space, one is cell gene. and the way to capture the plays without the risk on the high volatility with insight or clovis, both are expected to move 16 to 20% in the options market, just play ibb. take advantage of the fact that options prices are up. not only because of asco, but there are health care conferences. goldman sachs is having one. sell a put spread on ibb. the one that i'm looking at specifically is the july 225. sell the puts, and protect yourself for 6 bucks. you're collecting 40% of the distance between the strikes. you're taking adv

and the big mover, that was bristol meyers got downgraded after the data, with the immeow know thera if they do that after the downgrade. >> thanks for that. one thing you notice about the charts, most of the names peaked beginning of march. so will this help? >> yeah, the big space in bicycle tech was specifically the oncology drugs. t the cancer drugs in particular. that was the growth opportunities. they trade at astonishing multiples because their speculati speculative. a lot of companies in the same space, one is cell gene. and the way to capture the plays without the risk on the high volatility with insight or clovis, both are expected to move 16 to 20% in the options market, just play ibb. take advantage of the fact that options prices are up. not only because of this, but there are health care conferences. goldman sachs is having one. sell a put spread on ibb. the one that i'm looking at specifically is the july 225. sell the puts, and protect yourself for 6 bucks. you're collecting 40% of the distance between the strikes. you're taking advantage of the facts there's a lot of

so companies working in this space include bristol meyers, merck, novartis and astrazeneca.strazeneca's pipeline was one of the big reasons for pfizer interest in it. also companies like incite and celldex. the drugs could total $13 billion in peak annual revenue. this weekend will give us another glimpse at the promise of these medicines. >> meg, have a great weekend in chicago. great place to be in the summer. sue, down to you. >> yes, indeed. >>> well, you've just heard about some big medical breakthroughs. now let's find out what's happening in the world of start-ups from venture capitalist john lilly who's led the firm's investments in instagram, dropbox, tumblr and many others. he joins us live from the code conference in california. welcome. nice to have you here, john. >> thanks for having me. >> i know that there are some great conversations taking place out there. and one of them involves the internet. you wanted to talk a little bit about the internet of things. tell me what you mean by that and how the internet is changing from what it is now to what you think it

looking at stocks including bristol meyers merck, astrazeneca and including others cll incyte. will be important. switching directions a little bit over to mers. the world health organization saying they met and are even more concerned about the spread of mers. reaching 18 countries, including the netherlands reported today. there's been 536 cases confirmed by the world health organization. so far 145 deaths. again, this is mainly centered in the saudi arabia area, but we've had two cases here in the united states. now, i reached out today to two major vaccine-makers including merck and pfizer, they are not working on a advantages ian and some that i spoke with said this is appropriate saying that the spread is relatively limited right now. >> that's true. sars infected like 8,000 people in year one. troubling but not quite as bad so far, but thank you, meg. the nasdaq is down sharply and the russell 2000 has been the hardest hit so far today. >> coming up on the program. have you flapped lately? i'll speak exclusively with flappy bird's creator about becoming an overnight sens

bristole are mentioning meyer and squid. >> those are in the u.s.. >> let's talk about u.k.tion. we have inflation of course in up once is creeping again. it had been on a downward trend. accelerating more than forecast. getting a boost from easter last month. today compared with economists forecast. inflation creeping just up. just below the bank of england's target number of two percent. of course the report does expect inflation to remain at or near that level for the next two years. berlin's unfinished airport is d. ourquestione international correspondent hans nichols is at the berlin air show. good morning, hans. >> good morning, mark. i was tried to speak over the roar of the jet engines behind me. a whole phalanx of planes behind me. perhaps most interesting and qatar.c is the a350 from germany hasn't contributed its full amount to airbus's production of the a350. which is with airbus ceo fabrice bregier. they need to put their differences behind them. there are a variety of differences, namely between some of these gulf state carriers and berlin. they need to open t